Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036322 | 0.95 | ROCK2 (0.91) | ROCK2CYP3A4ROCK1MET | |
| SCHEMBL5258702 | 0.93 | ROCK2 (0.86) | ROCK2CYP3A4ROCK1MET | |
| SCHEMBL10036352 | 0.88 | ROCK2 (0.79) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL13116102 | 0.88 | ROCK2 (0.78) | ROCK2CYP3A4ROCK1MET | |
| SCHEMBL5257089 | 0.87 | ROCK2 (0.76) | ROCK2CYP3A4ROCK1MET | |
| SCHEMBL5256160 | 0.87 | ROCK2 (0.76) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL13115984 | 0.86 | ROCK2 (0.75) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL2879731 | 0.85 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL2880092 | 0.84 | ROCK2 (0.73) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL2880069 | 0.81 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 2878/4885ROCK1 2/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 2878/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.